{"filings":[{"id":582837,"accession_number":"0001612630-26-000054","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2026-05-21T20:32:11+00:00","items":["5.07","9.01"],"status":"ready","headline":"Joint Corp. shareholders elect all seven director nominees and approve say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected; votes for ranged from 9.88M (Rubel) to 10.81M (Razdan).","Advisory say-on-pay approved with 10.51M for, 342,867 against, and 3,625 abstentions.","Frequency of say-on-pay set to annual with 10.38M votes for one year, 461k for three years.","Ratification of BDO USA as auditor approved with 12.72M for, 9,364 against, 1,910 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94092,"accession_number":"0001612630-26-000048","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["1.01","2.03","2.02","7.01","9.01"],"status":"ready","headline":"JYNT Q1 revenue up 13%, net income up 34%; credit covenant default waived","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $14.8M (+13% YoY); net income from continuing ops $1.1M vs loss $506K prior year.","Consolidated diluted EPS $0.09 (vs $0.06); Adj EBITDA from consolidated ops $3.5M (+22%).","Credit default waived for fixed charge coverage ratio violation; JPM line extended to Aug 2029, $20M undrawn.","System-wide comp sales -4.2%; total clinic count 943 (down 17 vs Q4 2025).","Refranchised 45 clinics to Elite Chiro Group for $2.3M; repurchased 137K shares for $1.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":14820233.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94091,"accession_number":"0001612630-26-000039","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"The Joint Corp. sells 45 Southern California clinics for $2.3M, moves to pure franchisor model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["45 clinics sold to Elite Chiro Group for $2.3M; 13 closed on April 27, 2026.","32 clinics under management service agreement until lease assignments are completed.","After deal, corporate clinics drop to just 3 out of 960 total locations.","Part of 'The Joint 2.0' shift to capital-light, pure-play franchisor model.","Elite Chiro Group led by Gadi Emein and Michael Aminpour."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94090,"accession_number":"0001612630-26-000036","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Joint Corp. agrees to sell 45 Southern California clinics to Elite Chiro Group for $2.3M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total purchase price $2.3M, includes $150k non-refundable down payment; remainder paid into escrow.","Sale covers 45 company-owned/managed clinics in Southern California; clinics will convert to franchise agreements.","Buyer Elite Chiro Group also gets non-exclusive development rights for 10 additional clinics.","Closing for each clinic conditioned on lease assignment; proceeds allocated per clinic schedule.","Seller retains six other California clinics (Midtown Crossing, Inglewood, West Hollywood, Santa Monica, Mission Viejo, San Marcos)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106210,"accession_number":"0001612630-26-000018","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Joint Corp Q4 revenue $15.2M (+3.1% YoY); FY2025 net income $2.9M; guides FY2026 system-wide sales $519-552M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $15.2M (+3.1% YoY); net income from continuing ops $937K vs $909K.","FY2025 total revenue $54.9M; consolidated net income $2.9M vs net loss $5.8M in 2024.","Adjusted EBITDA from consolidated ops $13.0M (+13.9% YoY); FY2026 guidance $12.5-13.5M.","Refranchised 41 clinics in FY2025; 27 more in process; targets pure-play franchisor model.","Repurchased 1.3M shares for $11.3M in FY2025; $5.7M remaining on $12M buyback program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106208,"accession_number":"0001612630-26-000008","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K/A","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Joint Corp. agrees to nominate activist investor Jefferson Gramm to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Letter agreement with Bandera Partners LLC requires company to include Jefferson Gramm in director slate for 2026 annual meeting.","Bandera restricted from acquiring beneficial ownership beyond 3,937,296 shares until termination date.","Agreement remains in effect until earlier of 30 days before 2027 nomination deadline or January 21, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106209,"accession_number":"0001612630-26-000004","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Joint Corp. agrees to nominate activist investor Jefferson Gramm to board at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company will nominate Jefferson Gramm (Bandera Partners) and recommend his election at 2026 annual meeting.","Bandera agrees to standstill and not buy additional shares beyond current 3,937,296 JYNT shares until Jan 21, 2027.","Agreement includes voting commitments and transfer restrictions; termination date earlier of Jan 21, 2027 or 30 days before 2027 meeting.","Current beneficial ownership of Bandera is 3,937,296 shares; no additional purchases allowed except director grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122491,"accession_number":"0001612630-25-000074","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Joint Corp signs $1.5M APA for 22 SE clinics, terminates $4.5M APA for 45 CA clinics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold 22 clinics in VA, NC, SC for aggregate purchase price of $1,482,800; buyers are existing franchisees/operators.","Buyers will pay $100K down payment; remaining balance via promissory notes; lease assignments required for closing.","Delivered termination notice on Dec 11 for prior APA to sell 45 Southern California clinics for $4.5M due to buyer's failure to meet conditions.","No penalties for termination; company reiterates belief in franchise community expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122490,"accession_number":"0001612630-25-000066","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","2.02","7.01","8.01","9.01"],"status":"ready","headline":"Joint Corp Q3 net income turns positive to $855K; sells 45 clinics for $4.5M; adds $12M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $13.4M (+6% YoY); consolidated net income $855K vs loss of $3.2M in Q3 2024.","Adjusted EBITDA from continuing ops $1.4M vs $262K in Q3 2024; consolidated adjusted EBITDA $3.3M (+36%).","Agreed to sell 45 Southern California clinics for $4.5M via asset purchase agreement (terms still being negotiated).","Board authorized additional $12M for stock repurchase program; 540K shares bought for $5M since program start.","Lowered FY2025 system-wide sales guidance to $530-534M and comp sales to (1)% to 0% from prior low-single-digit growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":39728545.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122489,"accession_number":"0001612630-25-000060","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"The Joint Corp. to refranchise all company clinics; credit maturity extended to Aug 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Consent to refranchise 100% of company-owned/managed clinics to franchisees by Dec 31, 2025.","Revolving credit maturity extended to August 31, 2027; loan balance required to be $0 before/after each sale.","Each clinic disposition must be for fair value and at least 75% cash; fair value may be $0 for negative-earning clinics.","Amendment with JPMorgan Chase updates definitions and disposition allowances; no other material changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139189,"accession_number":"0001612630-25-000044","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Former CFO Jake Singleton to receive $171,959 severance, accrued PTO, and $15K under separation agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Jake Singleton's employment ended June 9, 2025; separation agreement signed Aug 22, 2025, includes general release of claims.","Separation benefits: lump-sum base salary of $171,958.50 (6 months), accrued PTO of $36,193.99, additional $15,000, plus up to 6 months COBRA.","No accelerated vesting of equity awards; terms governed by existing award agreements and equity plans.","Confidentiality, non-disparagement, and arbitration provisions apply; restrictive covenant agreement remains in effect.","Company agrees to provide neutral reference (job title and dates of employment) and directs two executives not to make knowingly false statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139188,"accession_number":"0001612630-25-000021","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Joint Corp Q2 rev $13.3M +5%, narrows loss; cuts FY system-wide sales guidance to $530-550M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $13.3M (+5% YoY); consolidated net income $93K vs loss $3.6M; net loss from continuing ops $990K vs loss $1.7M.","Adjusted EBITDA from continuing ops improved to $88K from loss $380K; consolidated Adj EBITDA up 52% to $3.2M.","Refranchised 37 clinics for $11.2M, acquired NW regional developer territory for $2.8M; franchised now 92% of 967 clinics.","Cuts FY 2025 system-wide sales guidance to $530-550M (from $550-570M); comp sales now low-single digit vs mid-single digit; raises consolidated Adj EBITDA guidance.","Announced restatement of 2024 10-K and Q1 2025 10-Q for non-cash impairment errors; no impact on Adj EBITDA."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":26347860.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139187,"accession_number":"0001612630-25-000015","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","4.02","9.01"],"status":"ready","headline":"The Joint Corp. to restate FY2024 and Q1 2025 results due to overestimated impairment charges by ~$2.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects to reduce 2024 net loss by ~$2.2M and increase carrying value of assets held for sale by ~$2.2M.","For Q1 2025, expects net income increase of ~$0.5M; cumulative carrying value increase of ~$2.7M.","No impact on Adjusted EBITDA or cash for either period.","Expects material weakness in internal controls and that disclosure controls were ineffective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139186,"accession_number":"0001612630-25-000009","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"The Joint Corp. closes sale of 31 clinics for $11.13M, acquires NW region RD rights","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold 31 company-owned clinics in AZ/NM to Joint Ventures, LLC for $11.13M (includes $8.3M cash).","Acquired regional developer rights for Northwest region (46 franchised clinics, 30 future sites).","Acquired RD rights generated $855,000 in royalties/fees in trailing 12 months ended March 31, 2025.","Pro forma shows net income from continuing operations of $88,979 for Q1 2025 vs prior loss of $506,021.","Transaction expected to reduce commission obligations and increase operating margin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156742,"accession_number":"0001612630-25-000006","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"The Joint sells 31 clinics for $11.07M, acquires NW region rights, refranchises 5 clinics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale of 31 corporate clinics to Joint Ventures, LLC for $11.07M; buyer to own 96 clinics total.","The Joint acquires regional developer rights for Northwest Region (46 existing+30 future sites).","Refranchised 5 Kansas City clinics to Chiro 93, LLC led by Dr. Clint Morrow.","Transaction expected to close on or before June 30, 2025; company to reduce RD commissions.","Company says deal improves profitability, tracks to become largest pure-play chiropractic franchise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156741,"accession_number":"0001628280-25-030452","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"The Joint Corp. names Scott J. Bowman CFO, replacing Jake Singleton","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott J. Bowman appointed CFO effective June 10, 2025; Jake Singleton separated June 9, 2025.","Bowman previously CFO at Leslie's, Dave & Buster's, Hibbett; 30+ years experience.","Employment agreement: $390,000 annual base salary; $250,000 initial equity grant under 2024 Incentive Stock Plan.","CEO Sanjiv Razdan cites Bowman's transformation and growth expertise for disciplined execution.","Bowman notes focus on multiphase strategy to reignite growth, reduce overhead, improve profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156740,"accession_number":"0001628280-25-029505","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"The Joint Corp. adds director Sandi Karrmann and authorizes $5M stock buyback","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Sandra R.A. Karrmann as director; board increases to eight; she will chair Compensation Committee.","Karrmann is an experienced HR executive from Kimberly-Clark, Tenet Healthcare, and Yum! Restaurants International.","Board approved up to $5M stock repurchase program, expected to begin August 2025, through June 3, 2027.","Repurchases may be made on open market or privately; no obligation to buy specific amount.","CEO says buyback reflects confidence in long-term strategy and refranchising program; stock undervalued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156739,"accession_number":"0001171843-25-003380","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Joint Corp. shareholders elect all seven director nominees, approve say-on-pay, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven Board nominees elected, including Matthew Rubel, Ronald DaVella, and Sanjiv Razdan.","Advisory vote on executive compensation approved with 10.66M for, 0.51M against.","Ratification of BDO USA, P.C. as independent auditor for FY2025 ratified with 12.74M for.","Broker non-votes of ~2.06M shares on director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156738,"accession_number":"0001628280-25-023805","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"The Joint Corp. Q1 revenue up 7% to $13.1M; net loss widens to $506k; reiterates 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $13.1M (+7% YoY); system-wide sales $132.6M (+5%); comp sales 3%.","Net loss from continuing ops $506k ($0.03/share) vs $399k in Q1 2024; adjusted EBITDA from continuing ops $46k vs $425k.","Reiterated FY2025 guidance: system-wide sales $550-570M; consolidated adj. EBITDA $10-11.5M; new franchised clinics 30-40.","Sold 9 franchise licenses; opened 5 franchised clinics; total clinics 969 (847 franchised).","Transitioning to pure-play franchisor with digital marketing and pricing initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":13077590.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175145,"accession_number":"0001628280-25-012616","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"The Joint Corp reports Q4 revenue up 14%, 2025 guidance for lower EBITDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue from continuing operations $14.4M (+14% YoY); net income $986k vs loss $10.2M.","System-wide sales $145.2M (+9% Q4), comp sales 6%. Full-year sales $530.3M (+9%).","2025 guidance: system-wide sales $550-570M, consolidated adj EBITDA $10-11.5M vs $11.4M in 2024.","New franchised clinic openings expected 30-40 in 2025 vs 57 in 2024; refranchising of corp clinics ongoing.","Comp plan amended: CEO STIP max up to 125% base salary if EBITDA exceeds budget; CFO up to 62.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175144,"accession_number":"0001171843-25-000293","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"The Joint Corp. reports 2024 operating metrics: 9% adjustment growth, LOIs received for majority of corporate clinics","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Performed 14.7 million patient visits in 2024, up from 13.6 million in 2023.","Treated 957,000 new patients, compared to 932,000 in 2023.","System-wide sales grew 9% in 2024, versus 12% in 2023.","Received letters of intent in early January to refranchise majority of corporate clinic portfolio.","Total clinic count expanded to 967 at year-end 2024, from 935 at end of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":51896605.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192085,"accession_number":"0001171843-24-007066","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"The Joint Corp. enters into Amended Nomination and Standstill Agreement with Bandera Partners","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Agreement dated Dec 19, 2024 amends prior standstill agreement between The Joint Corp. and Bandera Partners LLC.","Company agrees to nominate Jefferson Gramm to board at 2025 annual meeting and recommend stockholders vote for him.","Bandera agrees to standstill obligations, voting commitments, and restrictions on stock transfers until Jan 2, 2026 or earlier.","Bandera beneficially owns 3,937,296 shares of common stock as of agreement date.","Agreement includes director replacement rights and mutual non-disparagement provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192084,"accession_number":"0001628280-24-046293","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Joint Corp Q3 net loss $3.2M; guides down system-wide sales and new openings","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $30.2M (+2% YoY); net loss $3.2M vs $716K loss in Q3 2023, including $3.8M impairment.","Adjusted EBITDA fell to $2.4M from $2.9M; system-wide sales up 18% to $129.3M.","Guidance cut: system-wide sales now $525-535M (prior $530-545M); new franchised openings 55-60 (prior 60-75).","Total clinics 963 at Sept 30; sold 7 franchise licenses in Q3 vs 12 in Q3 2023.","Unrestricted cash $20.7M; $20M credit facility available through Feb 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":90181217.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192083,"accession_number":"0001171843-24-005643","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Joint Corp appoints Sanjiv Razdan as CEO; Peter Holt resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter D. Holt resigned as President/CEO and board member effective Oct 10, 2024.","Separation agreement: 12-month base salary continuation, $94K STI payment, 6-month COBRA; no accelerated equity vesting.","Sanjiv Razdan appointed President/CEO and board member effective Oct 14, 2024; base salary $550,000.","Inducement equity grants: 38,059 stock options at $10.51 and 38,059 RSUs, each vesting over 4 years.","Razdan previously President Americas & India at Coffee Bean & Tea Leaf, COO at Sweetgreen, SVP at Applebee's."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208575,"accession_number":"0001628280-24-036150","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Joint Corp Q2 net loss $3.6M ($0.24/sh); revenue $30.3M up 3% YoY; guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.6M ($0.24 loss per share) vs net loss $320K ($0.02 loss) in Q2 2023.","Revenue $30.3M +3% YoY; system-wide sales $129.6M +8%; comp sales +2%.","Adjusted EBITDA $2.1M vs $3.2M; includes $1.5M litigation expense and $1.4M impairment.","Sold 7 franchise licenses (vs 21); total clinics 960; over 10 refranchise LOIs in progress.","2024 guidance reiterated: system-wide sales $530-545M, mid-single digit comps, 60-75 new clinics."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":59982727.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226285,"accession_number":"0001171843-24-003088","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Joint Corp. stockholders approve 2024 Incentive Stock Plan with 2M shares authorized","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan authorizes up to 2,000,000 shares for stock options, SARs, restricted stock, and RSUs.","Approval vote: 8,194,262 for, 2,307,064 against; plan effective May 22, 2024.","Seven director nominees elected; CEO Peter D. Holt received 10,438,521 votes for.","Say-on-pay advisory vote passed (10,377,686 for); auditor BDO USA ratified (12,424,642 for).","Plan includes performance-based vesting, 10-year term, and change-in-control provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226284,"accession_number":"0001612630-24-000003","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Joint Corp Q1 rev $29.7M (+5% YoY), operating income $1.1M, reiterates guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $29.7M (+5% YoY); operating income $1.1M vs loss $653k; net income $0.06/diluted share.","Adjusted EBITDA $3.5M (+75% from $2.0M); system-wide comp sales +3%.","Opened 23 franchised clinics; total clinic count 954; sold 15 franchise licenses, triple Q4 2023's 5.","FY 2024 guidance reiterated: system-wide sales $530-545M, new franchised openings 60-75 (excl. refranchising).","Hired investment bank specializing in refranchising to accelerate corporate clinic portfolio transition."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":29722166.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245327,"accession_number":"0001171843-24-001235","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"The Joint Corp. Reports Q4 2023 Revenue $30.6M, Full Year $117.7M, Net Loss $9.8M on Valuation Allowance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue grew 11% to $30.6M; system-wide sales up 11% to $133.1M","Full year 2023 revenue increased 16% to $117.7M; system-wide sales rose 12% to $488.0M","Reported net loss of $9.8M for 2023 including $10.8M non-cash valuation allowance; net income of $627K in 2022","Adjusted EBITDA for 2023 was $12.2M, up from $11.5M in 2022; clinic count grew to 935 from 838","Initiated refranchising program for majority of corporate clinics; 2024 guidance for system-wide sales $530M-$545M"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262784,"accession_number":"0001171843-23-006953","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Joint Corp Q3 net loss $716K; plans to refranchise majority of corporate clinics","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $29.5M (+11% YoY); net loss $0.05/sh vs income $0.05/sh in Q3 2022.","Operating loss $898K vs operating income $732K; Adj EBITDA $2.9M vs $3.1M.","System-wide sales +8% to $119.3M; comp sales flat; total clinics 914.","Board authorized plan to refranchise/sell majority of corporate-owned clinics.","Reaffirmed FY 2023 guidance: revenue $115-118M, Adj EBITDA $11-12.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":87081953.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262783,"accession_number":"0001628280-23-037571","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"The Joint Corp. appoints Jeff Gramm to board, enters standstill with Bandera Partners (26.69% holder)","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gramm (Bandera portfolio manager) appointed to board effective Jan 2, 2024; will stand for election at 2024 annual meeting.","Bandera owns ~3.94M shares (26.69% of outstanding); standstill limits ownership and includes voting commitments.","Standstill runs through earlier of Jan 2, 2025 or 30 days before 2025 annual meeting nomination deadline.","Board size remains at seven; Gramm fills a vacated seat."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279970,"accession_number":"0001171843-23-005715","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K/A","filed_at":"2023-09-15T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"The Joint Corp. restates financials for FY2021-FY2022 due to material errors; warns of credit covenant risk","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restatement covers audited FY2021, FY2022, and interim 2021/2022 quarters; all prior financial statements no longer reliable.","Material errors identified by CFO after meeting with Audit Committee; BDO USA concurred; Board ratified on Sep 11, 2023.","Credit facility covenant breach possible if Q2 2023 Form 10-Q not filed by Sep 30, 2023; one-time waiver obtained but lender could demand immediate repayment.","Legal risks and increased compliance costs cited as additional forward-looking uncertainties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279975,"accession_number":"0001171843-23-005696","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2023-09-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Joint Corp. Q2 prelim: rev $29.3M (+18%), Adj EBITDA $3.2M (+23%), cuts FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $29.3M (+18% YoY); operating loss improved to $0.375M from $1.3M loss in Q2 2022.","Adjusted EBITDA $3.2M (+23% YoY); system-wide sales $120.1M (+13%); comp sales +5%.","FY 2023 revenue guidance cut to $115-118M from $123-128M; Adj EBITDA cut to $11-12.5M from $12.5-14M.","Plans to cull ~10% of corporate clinic portfolio via accretive transactions to improve profitability.","Cash $13.6M; opened 26 new clinics in Q2; total clinics 890 at quarter end, 911 as of Sept 12."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279974,"accession_number":"0001171843-23-005680","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["2.04"],"status":"ready","headline":"JPMorgan grants temporary waiver of default under $20M revolver until Sept 30 for late Q2 10-Q filing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Default triggered by failure to timely file Q2 2023 10-Q; JPMorgan waived until Sept 30, 2023.","Outstanding $2M principal plus $36,150 interest on senior secured revolver; no other covenant breach.","If not cured by Sept 30, credit facility may accelerate, interest rate rise 2%.","Company holds $14.8M unrestricted cash as of Aug 31, 2023, sufficient to cover outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279973,"accession_number":"0001171843-23-005590","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["2.02","4.02","9.01"],"status":"ready","headline":"The Joint Corp. to restate 2022 results; net income to drop $0.6M due to accounting errors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restating 2022 annual and interim financials for re-acquired regional developer rights and VIE transfer pricing errors.","Estimated FY2022 net income reduction of $0.6M; no change to adjusted EBITDA or cash.","Expects one or more material weaknesses in internal controls; evaluating remedial measures.","Plans to file 10-K/A and then Q2 2023 10-Q; conference call to follow.","Prior financials for 2022 and certain 2021 periods should no longer be relied upon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279972,"accession_number":"0001171843-23-005436","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2023-08-25T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Joint Corp. gets Nasdaq delinquency notice for late Q2 2023 10-Q filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice received Aug 22, 2023 due to failure to file Q2 2023 Form 10-Q by Aug 21 deadline.","Company has until Oct 23, 2023 to submit a plan of compliance to Nasdaq.","Delay caused by ongoing evaluation of accounting treatment for regional developer arrangements.","Company states it will work to file the 10-Q as soon as practicable and regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279971,"accession_number":"0001171843-23-005230","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"The Joint Corp. Q2 system-wide sales +13% to $120.1M; financial results postponed due to review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["System-wide sales $120.1M (+13% YoY); system-wide comp sales +5%.","Clinic count 890 at June 30; subsequent openings brought total to 900 in August 2023.","Unrestricted cash $13.6M (Dec 2022: $9.7M); operating cash flow $8.4M including $4.8M ERC.","Financial results postponed due to ongoing review of regional developer arrangements (non-cash impact).","Sold 21 franchise licenses in Q2; opened 26 new clinics, closed 6."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":57608005.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298482,"accession_number":"0001171843-23-003582","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Joint Corp. shareholders approve 1.2M share increase to 2014 incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stock plan share reserve increased from 2,213,000 to 3,413,000 shares; approved with 9,106,006 votes for.","Six directors elected: Matthew Rubel, Ronald DaVella, Suzanne Decker, Peter Holt, Abe Hong, Glenn Krevlin.","Say-on-pay approved with 9,449,668 votes for (97.3% of votes cast).","BDO USA ratified as auditor for FY2023 with 11,451,970 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298481,"accession_number":"0001171843-23-002890","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Joint Corp Q1 revenue up 27% to $28.5M; net income $2.3M includes $3.9M ERC credits","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $28.5M (+27% YoY); system-wide sales $115.4M (+17%); system-wide comp sales +8%.","Operating loss $678K vs loss $176K YoY; net income $2.3M ($0.15 diluted) vs net loss $206K, includes $3.9M ERC.","Adjusted EBITDA $2.0M vs $1.8M; clinic count 870 (740 franchised, 130 co-owned), up 32 from Dec 2022.","2023 guidance reaffirmed: revenue $123-128M, Adj. EBITDA $12.5-14.0M, franchised openings 100-120, co-owned greenfield 8-12.","Opened greenfield clinic at Fort Dix in April; fourth with Army & Air Force Exchange Service."],"consensus_eps_estimate":null,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":28450298.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298480,"accession_number":"0001171843-23-002585","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Joint Corp. adopts amended bylaws for DGCL updates and universal proxy rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Third Amended and Restated Bylaws effective April 20, 2023.","Updated advance notice provisions for stockholder nominations and business proposals to comply with Rule 14a-19.","Revised proxy access section to address meeting date changes and exclusive method for including nominees.","Removed requirement for voting list at meetings per recent DGCL amendments.","Conforming and clarifying changes to adjournment notice and stockholder meeting procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318686,"accession_number":"0001171843-23-001615","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Joint Corp. director James H. Amos Jr. not standing for reelection; CFO salary increased to $300K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James H. Amos Jr. will not stand for reelection at the May 25, 2023 annual meeting; board reduces to six.","CFO Jake Singleton's base salary raised from $257,500 to $300,000 retroactive to Jan 1, 2023.","Singleton's annual bonus target increased to 50% of base (max 62.5% if performance targets exceeded).","Amos cites personal reasons; no disagreement with company over operations or policies.","System-wide sales grew sixfold from $70.1M in 2015 to $435.3M in 2022, per press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318685,"accession_number":"0001171843-23-001550","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"The Joint Corp. Q4 revenue up 26% to $27.8M; net income $547K vs loss $360K; guides 2023 revenue $123M-$128M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $27.8M (+26% YoY); system-wide comp sales +8%; total clinics 838 at year-end.","Q4 net income $547K ($0.04 diluted EPS) vs net loss $360K ($0.02 loss) YoY; Adjusted EBITDA $4.0M vs $2.1M.","Full-year 2022 revenue $101.9M (+26%); net income $1.2M ($0.08 EPS) vs $6.6M ($0.44 EPS) in 2021.","2023 guidance: revenue $123M-$128M, Adjusted EBITDA $12.5M-$14.0M; franchised clinic openings 100-120, company greenfields 8-12.","Acquired 16 previously franchised clinics in 2022; cash balance $9.7M at year-end vs $19.5M in 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336906,"accession_number":"0001171843-22-007076","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"The Joint Corp Q3 revenue +27% to $26.6M; net income drops to $491k; lowers EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $26.6M (+27% YoY); net income $491k ($0.03 EPS) vs $1.9M ($0.13) in Q3 2021.","System-wide sales $110.4M (+18%); system-wide comp sales +6%; 38 clinics opened in quarter.","Total clinics 805 (690 franchised, 115 company-owned/managed) at Sept 30, 2022.","Adjusted EBITDA $3.1M vs $3.3M last year; 2022 guidance: revenue $100-102M, EBITDA $11.5-12.5M (lowered from $12-14M).","Reacquired Philadelphia RD territory; acquired 2 clinics and sold 1 corporate clinic post-quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":74098856.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354294,"accession_number":"0001171843-22-005358","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"The Joint Corp Q2 revenue rises 24% to $25.1M, net income plunges to $345k from $2.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $25.1M (+24% YoY); net income $345k ($0.02 EPS) vs $2.7M ($0.18) prior year.","Adjusted EBITDA $2.6M, down from $3.8M; operating income $473k vs $2.0M.","System-wide sales $106M (+21%); system-wide comp sales +8%; total clinics 769 (+33 net).","Cash $9.4M at June 30, down from $19.5M at Dec 31 due to clinic acquisitions and greenfields.","FY 2022 guidance reaffirmed: revenue $98-102M, Adj EBITDA $12-14M, franchised openings 110-130."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":47495856.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372239,"accession_number":"0001171843-22-004038","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2022-05-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Joint Corp. stockholders approve all proposals at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Seven director nominees elected with majority votes; highest vote count 9,271,653 for Glenn J. Krevlin.","Advisory vote on executive compensation approved: 9,069,656 for, 223,795 against.","Ratification of BDO USA as independent auditor for FY 2022: 10,485,665 for, 55,772 against.","Broker non-votes on director elections and executive compensation: 1,262,417."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372238,"accession_number":"0001171843-22-003875","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2022-05-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"The Joint Corp. acquires four franchised clinics for $5.8M; expects immediate accretion","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration $5.8M: $5.6M cash at close, $200K within 90 days.","Clinics located in Scottsdale/Phoenix region; company will operate as company-owned.","Expected to be immediately accretive to bottom line and improve corporate clinic margin.","Seller was multi-unit franchisee consolidating to California; valuation in-line with prior deals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372237,"accession_number":"0001171843-22-003330","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"The Joint Corp. Q1 revenue $22.4M (+28% YoY); net loss $206K; adj. EBITDA $1.8M; updates guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $22.4M, up 28% YoY; system-wide sales $98.8M (+27%); comp sales +15%.","Net loss $206K ($0.01/sh) vs net income $2.3M ($0.16 diluted) in Q1 2021.","Adjusted EBITDA $1.8M, down from $3.5M; operating loss $176K vs profit $2.0M.","Opened 31 clinics (27 franchised, 4 greenfield) – record Q1; total clinics 736.","Guidance updated: FY rev $98-102M; adj. EBITDA $12-14M; 110-130 franchised openings."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":22438538.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391099,"accession_number":"0001171843-22-001641","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2022-03-04T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Joint Corp. expands senior secured revolver to $20M; uncommitted line to $30M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolver increased from $2M to $20M; letter of credit subfacility from $1M to $5M.","Uncommitted additional line of credit raised to $30M (from $2.5M); $5.5M developmental line terminated.","Maturity extended to February 28, 2027; interest at SOFR+0.10%+1.75% or ABR+1.00%.","Proceeds intended for working capital, acquisitions, development, and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391097,"accession_number":"0001171843-22-001345","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K/A","filed_at":"2022-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Joint Corp. reports 38% revenue growth in FY2021; corrects 2022 clinic opening guidance to 110-130","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $22.4M (+32% YoY); net income $224K vs $10.6M (prior year benefitted from $8.9M tax valuation allowance reversal).","Full-year revenue $81.2M (+38%); Adjusted EBITDA $13.3M (+46%); system-wide comp sales +29%.","Opened 130 clinics in 2021 (110 franchised, 20 greenfield); total clinics 706 at year-end.","2022 guidance: revenue $102-106M, Adjusted EBITDA $15-17M; franchised openings corrected to 110-130 from 130-140.","Cash $19.5M at Dec 31, 2021; sold 156 franchise licenses in 2021 vs 121 in 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":80859653.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391098,"accession_number":"0001171843-22-001324","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Joint Corp. Q4 revenue $22.4M (+32% YoY); net income $224K; guides FY22 rev $102-106M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2021 revenue $81.2M (+38% YoY); system-wide sales $361.1M (+39%).","Net income $7.2M for 2021 vs. $13.2M in 2020; Adjusted EBITDA $13.3M vs. $9.1M.","Opened 130 clinics in 2021 (110 franchised, 20 greenfield); total 706 clinics at year-end.","Q4 net income $224K ($0.01 diluted EPS) vs. $10.6M ($0.72) in Q4 2020, which included $8.9M tax benefit.","Guides 2022 revenue $102-106M, Adjusted EBITDA $15-17M, and 160-180 total new clinics."],"consensus_eps_estimate":null,"consensus_eps_actual":0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":80859653.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409235,"accession_number":"0001171843-21-007559","cik":1612630,"company_name":"JOINT Corp","ticker":"JYNT","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Joint Corp Q3 revenue $21.0M (+36% YoY), net income $1.9M; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $21.0M (+36% YoY), system-wide sales $93.4M (+37%), system-wide comp sales +27%.","Net income $1.9M ($0.13 diluted EPS) vs $1.6M ($0.11); Adjusted EBITDA $3.3M vs $2.6M.","Sold 44 franchise licenses (vs 30); total clinics 666 (583 franchised, 83 company-owned).","Raised 2021 guidance: revenue to $80-81M, Adjusted EBITDA to $13-14M, franchise openings to 105-115.","Post-quarter: opened 1 greenfield, acquired 4 franchised clinics; company-owned/managed now 88."],"consensus_eps_estimate":null,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":58758383.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":133002854.91290325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-04T23:59:59+00:00|409235"}